NPM1 mutations frequently co-occur together with FLT3-ITD mutations, which counteracts a favorable prognosis that is observed for AML patients that only have a NPM1 mutation but no FLT3 mutation12,47,53. This evidence concerns the gene FLT3 and acute myeloid leukemia.